0001209191-20-009652.txt : 20200214 0001209191-20-009652.hdr.sgml : 20200214 20200214162259 ACCESSION NUMBER: 0001209191-20-009652 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200213 FILED AS OF DATE: 20200214 DATE AS OF CHANGE: 20200214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cui Jingrong Jean CENTRAL INDEX KEY: 0001772259 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38871 FILM NUMBER: 20620366 MAIL ADDRESS: STREET 1: C/O TURNING POINT THERAPEUTICS, INC. STREET 2: 10628 SCIENCE CENTER DR., STE. 225 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Turning Point Therapeutics, Inc. CENTRAL INDEX KEY: 0001595893 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463826166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-926-5251 MAIL ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, Inc. DATE OF NAME CHANGE: 20181018 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, INC DATE OF NAME CHANGE: 20140106 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-13 0 0001595893 Turning Point Therapeutics, Inc. TPTX 0001772259 Cui Jingrong Jean C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, STE. 200 SAN DIEGO CA 92121 1 0 0 0 Common Stock 1301298 D Common Stock 2020-02-13 4 S 0 200 59.83 D 792519 I By spouse Common Stock 2020-02-13 4 S 0 2400 60.70 D 790119 I By spouse Common Stock 2020-02-13 4 S 0 8800 62.18 D 781319 I By spouse Common Stock 2020-02-13 4 S 0 100 63.07 D 781219 I By spouse Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. The weighted average sale price for the transaction reported was $59.83, and the range of prices were between $59.46 and $60.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $60.70, and the range of prices were between $60.47 and $61.45. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $62.18, and the range of prices were between $61.79 and $62.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. /s/ Annette North, Attorney-in-Fact 2020-02-14